VivoSeq
Nephrology

Idiopathic Nephrotic Syndrome

12

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Idiopathic Nephrotic Syndrome is an emerging landscape with 12 programs across 8 companies. The most active players are Novartis, Roche, Pfizer. 1 therapy is approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

38/100

Completion Rate

71/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2Roche logo

Roche

4 programs

Phase 3Pfizer logo

Pfizer

1 program

Phase 3K

Kenvue Brands

1 program

Phase 3AbbVie logo

AbbVie

1 program

Phase 3O

OM Pharma SA

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

10 of 13 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody323%

Small molecule leads; the ring shows all 13 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

17

clinical trials

Unknown status8 · 47%
Completed5 · 29%
Active, not recruiting1 · 6%
Withdrawn1 · 6%
Terminated1 · 6%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

17 trials

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
Active, not recruiting·Roche logoRoche·Phase 3·NCT05627557·85 enrolled
Comparison of Efficacy and Safety of Albumin Versus Fresh Frozen Plasma in Managing Diuretic Resistant Edema in Children With Idiopathic Nephrotic Syndrome
Not yet recruiting·—·Preclinical·NCT07685093·56 enrolled
Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome
Completed·—·Phase 2·NCT04783675·44 enrolled
Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study
Completed·NNanjing University School of Medicine·N/A·NCT02298335·235 enrolled
Rituximab for Idiopathic Nephrotic Syndrome
Completed·—·Phase 3·NCT04494438·30 enrolled
Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome
Completed·—·Phase 2·NCT02394119·140 enrolled
Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Syndrome
Completed·NNishtar Medical University·N/A·NCT04818723·106 enrolled
Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome
Terminated·—·Phase 2·NCT02394106·13 enrolled
Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study
Withdrawn·UUniversity Hospital, Limoges·Phase 2·NCT02997150
Valproic Acid for Idiopathic Nephrotic Syndrome
Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2/3·NCT02896270·15 enrolled
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
Unknown status·RRadboud University Medical Center·Phase 3·NCT03298698·40 enrolled
Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome
Unknown status·NNational and Kapodistrian University of Athens·Phase 4·NCT01346007·50 enrolled
Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome
Unknown status·—·N/A·NCT05044169·83 enrolled
Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.
Unknown status·—·Phase 2·NCT04585152·160 enrolled
Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome
Unknown status·NNational University Health System, Singapore·Phase 3·NCT03501459·100 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)